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REPLY: Recognizing Sex Similaritiesin Cardiovascular Disease Research
Copper, Coronary Heart Disease,
and DehydroepiandrosteroneAspects of gender and biological sex are important to
address in research, and we thank Dr. Shufelt and
colleagues for their letter. Certainly it would have
been suitable to address the association between de-
hydroepiandrosterone (DHEA), its sulfate, and car-
diovascular risk in women in the discussion of our
paper (1), even if women were not included in
the MrOS cohort. The data by Shufelt et al. (2) are
interesting and suggest an association between low
DHEA-S and cardiovascular risk in women as in men,
whereas other studies have suggested a U-shaped
association in women (3).
We also thank Dr. Klevay for sharing his hypothesis
regarding copper, coronary heart disease, and DHEA,
proposing that low DHEA may be a sign of copper
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Aspirin Treatment and
Outcomes After
Percutaneous Coronary
InterventionResults of the ISAR-ASPI RegistryWe read with great interest the paper by Mayer et al.
(1) demonstrating an association between high
on-aspirin treatment platelet reactivity and cardio-
vascular complications in patients undergoing per-
cutaneous coronary intervention. We would like to
congratulate the investigators for this pivotal study
and suggest that they consider prior aspirin use as
another variable contributing to adverse outcomes. In
fact, we believe that the larger number of patients
with high on-aspirin treatment platelet reactivity in
the ISAR-ASPI (Intracoronary Stenting and Antith-
rombotic Regimen—Aspirin and Platelet Inhibition)
registry compared with other populations using tests
speciﬁc for COX-1 activity (2,3) may be due to the
higher percent of patients receiving aspirin treatment
at the time of hospital admission.
Such consideration follows our demonstration that
human megakaryocytes have an adaptive response to
aspirin, leading to up-regulation of platelet multidrug
resistance protein 4 (MRP4) (4). Aspirin effects are
reduced in patients undergoing coronary artery by-
pass grafting because of platelet MRP4 overex-
pression, because aspirin is an MRP4 substrate.
Moreover, with long-term drug exposure, eukaryotic
cells may trigger speciﬁc genes leading to cellular
mechanisms modulating their effects.
Because MRP4 inhibition reduces collagen-induced
platelet activation, we hypothesized that platelets
with MRP4 overexpression may be hyperresponsive.
A reduction of aspirin-dependent platelet inhibition
over time is well established. In fact, aspirin-treated
healthy volunteers, either at high (1,300 mg/day)
or low (100 mg/day) concentrations, showed reduced
platelet aggregation in the early weeks of treatment,
